舒巴坦-度洛巴坦用于肺移植术后抗感染治疗

Sulbactam-durlobactam for anti-infection treatment after lung transplantation

  • 摘要:
    目的  总结国内首例舒巴坦-度洛巴坦治疗肺移植术后广泛耐药鲍曼不动杆菌感染的临床经验。
    方法  回顾1例重度慢性阻塞性肺疾病患者肺移植术后接受舒巴坦-度洛巴坦治疗的病例。
    结果  68岁男性,术前有耐药鲍曼不动杆菌感染史,术后感染加重伴肾功能受损,痰培养为广泛耐药鲍曼不动杆菌。在接受舒巴坦-度洛巴坦联合美罗培南治疗后,感染得到控制,移植肺功能恢复。
    结论  舒巴坦-度洛巴坦对肺移植术后广泛耐药鲍曼不动杆菌感染具有潜在治疗价值,为临床提供了新策略。

     

    Abstract:
    Objective  To summarize the clinical experience of the first case of sulbactam-durlobactam treatment for extensively drug-resistant Acinetobacter baumannii infection after lung transplantation in China.
    Methods  A retrospective analysis was conducted on a case of a patient with severe chronic obstructive pulmonary disease who received sulbactam-durlobactam treatment after lung transplantation.
    Results  A 68-year-old male patient with a history of drug-resistant Acinetobacter baumannii infection before surgery, experienced worsening infection and impaired renal function after lung transplantation, with sputum culture showing extensively drug-resistant Acinetobacter baumannii. After receiving combination treatment with sulbactam-durlobactam and meropenem, the infection was controlled, and the function of the transplanted lung was restored.
    Conclusions  Sulbactam-durlobactam has potential therapeutic value for extensively drug-resistant Acinetobacter baumannii infection after lung transplantation and provides a new strategy for clinical practice.

     

/

返回文章
返回